Introduction
Characterization of the ability of type I IFNs (e.g., IFN-α) to rapidly activate genes led to the identification of ISGF-3, a transcription factor consisting of Stat1, Stat2 and an IRF-9 DNA binding protein 1 . Subsequently, IFN-γ was shown to induce genes through Stat1 homodimers 2 .
To date, seven STATs (Signal transducers and activators of transcription) have been identified in vertebrates, all of which are activated by phosphorylation on a single tyrosine (Y701 in Stat1; reviewed in 3,4). Activation drives STAT dimerization by directing a stable and specific association between the phosphotyrosine of one STAT and the SH2 domain of a partner STAT 5 .
Residues located at positions +1, +3, +5, +6 and +7 carboxy terminal to this phosphotyrosine (i.e., amino acids 702, 704, 706 and 707 for Stat1) determine the specificity of this interaction 6 .
Dimerized STATs translocate to the nucleus, where they bind to members of the GAS (gamma activated site) family of enhancers, culminating in the induction genes 3, 4 .
The regulation of STAT signal decay has also been an area of active investigation. Four major classes of counter regulatory molecules have been identified, including phosphatases 3,4,7 ,
nuclear "transportases" [8] [9] [10] , covalent modifiers 4, 11, 12 and specific STAT counter-regulatory proteins (e.g., SOCS and PIAS proteins 13, 14 )
. Studies on SOCS-1 have provided significant evidence for a critical role in down regulating IFNγ-Stat1 dependent signals, but studies on PIAS (Protein Inhibitor of Activated STATs) proteins have yielded less direct mechanistic insight into Stat1 regulation [14] [15] [16] . More recent studies have determined that PIAS proteins are SUMO E3
ligases (see below), raising the possibility that STAT activity is regulated through SUMO modification [17] [18] [19] .
SUMOs (Small Ubiquitin-related Modifiers) are ~100 amino acid peptides, which like ubiquitin, become covalently attached to cellular target proteins (reviewed in 17, 18, 19) .
However, in contrast to ubiquitin, SUMO modifications do not target proteins for degradation, but rather promote protein-protein interactions, direct subcellular localization and/or serve to antagonize ubiquitin dependent degradation. SUMO conjugation entails the formation of a reversible isopeptide bond between the C-terminus of the SUMO peptide (SUMO-1, SUMO-2 or SUMO-3) and the ε amino group of the lysine found in the consensus sequence ψKxE (ψ = hydrophobic residue, "x" = any residue; see Table 1 ). Analogous to ubiquitin, SUMO conjugation is mediated by an ATP-dependent E1 activating complex (i.e., Aos1+Uba2), an E2
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From 4 ligation complex (i.e., Ubc9) and an E3 conjugation complex. The relative specificity exhibited by Ubc9 for some SUMO substrates is likely to account for E3 independent SUMO conjugation observed in vitro 20, 21 . Finally, isopeptidases from the SUSP/SENP family assure that SUMO modification is reversible 18, 22 .
Sequence analysis revealed two potential SUMO modification sites, 109 Table 1 ). Efforts to exploit SUMO-1 specific antibodies to detect endogenous SUMO-modified Stat1 were unsuccessful. To improve the chances of detecting this product, Ubc9 and HA-SUMO-1 were over expressed in HEK-293T cells. Under (A) HEK-293T cells were transfected with HA-SUMO-1, Ubc9 and/or PIASy. 48 hrs later they were stimulated with IFN-γ (3 ng/ml; 30 min. 
Stat1 is SUMO modified at Lysine 703
To develop more direct evidence for Stat1 SUMO modification and to map the SUMOylation site, we turned to an effective in vitro conjugation assay that overcomes limitations imposed by SUMO deconjugating enzymes 20, 22, 26 . Purified recombinant Stat1 was incubated with purified active preparations of human recombinant SUMO-1, E1 (Uba2/Aos1), E2 (Ubc9), and E3 (Nup358 or PIAS1) 20, 21, 27 . After one hour, the products were fractionated by SDS-PAGE and immunoblotted with a Stat1 specific antibody. As shown in Figure 2 phosphorylation precludes SUMO modification, as suggested by HEK-293T over expression studies ( Fig. 1) , a Stat1 phospho-peptide (i.e., phospho-Y701) was also evaluated. Again, p53
peptides spanning a well characterized SUMOylation site served as important controls 20 . After 5 and 24 hours of SUMO conjugation, only the wild type Stat1 peptide was SUMOylated as effectively as the control wild type p53 peptide (see Fig. 2B ). More detailed kinetic studies provided further evidence that wild type Stat1 was an effective SUMO substrate, whereas Stat3, phospho-Stat1 and the mutant peptides were poor substrates (Fig. 2C ). These data confirmed only.
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The failure to SUMOylate the Stat3 peptide was consistent with our inability to modify purified preparations of recombinant Stat3 9 (data not shown), reflecting a critical divergence in the corresponding potential Stat3 SUMO conjugation site (see Table 1 ).
Stat1

K703R exhibits enhanced DNA binding activity
To explore the potential role of Stat1 SUMO modification in vivo, a SUMOylation resistant Stat1 K703R mutant was generated. Retroviral vectors directed expression of Stat1 anticipated, no differences were observed in ISGF3-ISRE DNA binding activity in IFN-α stimulated extracts, where IRF-9 mediates DNA binding (data not shown). In sum, these studies demonstrate that mutation of lysine 703 to arginine significantly enhanced Stat1 GAS binding activity in response to IFN-γ stimulation, recently also reported in human U3A cells 23 .
Analysis of additional Stat1 SUMOylation defective mutant
To develop additional evidence that Stat1 was SUMO modified at K703 in vivo, a second critical amino acid in the Stat1 SUMO consensus modification site (i.e., E705), which is also not involved in dimerization, was mutated to alanine 6, 17, 18 For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From (Fig. 4A, top panel) . To confirm that both mutants were defective in SUMO modification, HA-SUMO-1 and Ubc9 were over expressed in these MEFs. Despite modest transfection efficiency in these MEFs (see Fig. 4A, bottom panel) , the studies clearly demonstrate the formation of the ~105 kDa SUMO-Stat1 conjugate in cells expressing wild type Stat1, but not in those cells expressing the SUMOylation defective mutants, Stat1 K703R and Stat1 E705A (Fig. 4A, top panel) .
Next, the IFN-γ dependent activation of Stat1 E705A was evaluated. Stat1 E705A exhibited a pattern of activation (i.e., tyrosine phosphorylation) and DNA binding that was identical to that 
Likewise Stat1
K703R exhibited an essentially normal pattern of tyrosine phosphorylation, notable for a slight delay at early time points and more robust activity at later time points (Fig. 4B) .
However, these modest changes in IFN-γ dependent Stat1 K703R tyrosine phosphorylation correlated with a striking increase in DNA binding activity (Fig. 4C) ), as in Figure 4 , were stimulated with IFN-γ (50 U/ml; 0, 0.5, and 6 h). Cells were fixed and either imaged for the expression of a GFP reporter gene or after immuno-staining with anti-Stat1. Cells were examined under a 40-x Nikon epifluorescence objective. Data are representative of more than three independent studies. ), were transiently transfected with a GAS driven luciferase reporter (B2SH-WT3-Luc) in triplicate and stimulated with IFN-γ (50 U/ml; 6 h). Samples were harvested and evaluated for luciferase and renilla activity (in arbitrary light units). Data are representative of two independent experiments. (C) Immunoblot demonstrates that Stat1 expression (wild type and mutants) was similar in all three Stat1 expressing lines.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From gene expression at 2 and 6 hours post stimulation, followed by normalization of expression by 12 hours (Fig. 6A) . Changes in the expression of a GAS-driven reporter gene, which tends to measure a more averaged transcriptional response, did not reveal any statistically significant differences between wild type, Stat1 E705A or Stat1 K703R ( Fig. 6B; (Fig. 7B, top panel ) [34] [35] [36] . Modest differences between the capacity of wild type and mutant Stat1 to direct NO production appeared correlated with differences in the level of Stat1 expression. Next, the Stat1 dependent ability of IFN-γ to induce MHC II expression in Stat1
"transduced" (i.e., GFP + ) macrophages was evaluated by FACS (Fig. 7B , bottom panel) 34 . 19, 26, 30, 31, 37, 38 . When STAT sequences were scanned for the SUMO consensus modification site, only two potential sties were identified in Stat1, but not in other STATs (see Table 1 ).
Biochemical studies identified lysine 703, adjacent to the activation tyrosine (i.e., Y701), as the SUMO conjugation site. However, the inability to recover tyrosine phosphorylated SUMO-Stat1
conjugates in the HEK-293T cells raised concern over whether a single Stat1 molecule could be simultaneously modified at both Y701 and K703 (Fig. 1) . Consistent with this, a tyrosine phosphorylated Stat1 peptide was a poor substrate for in vitro SUMO modification (Fig. 2) .
To evaluate the potential physiological significance of SUMO Stat1 conjugation, SUMOylation defective Stat1 mutants were generated. Fortuitously, the two most critical residues in the SUMO consensus modification site, K703 and E705, are exposed, suggesting they could be mutated without perturbing Stat1 activity 6, 24 . For 9, 34 . NO production was evaluated at day 10 of culture and 72 hrs after IFN-γ (50 U/ml) and/or LPS (2 μg/ml) stimulation, as previously described 35 .
Materials and methods
Biochemical studies: Recombinant SUMO-1, E1, and E2 were expressed, purified and assayed as previously described 20 . The IR1-M-IR2 domains of Nup358 (aa 2596-2836) and full-length PIAS1 (aa 1-651) were cloned and expressed as Smt3 fusion proteins, cleaved by Ulp1, and purified by anion exchange and gel filtration chromatography 42 . To assay for Stat1
SUMOylation, purified recombinant Stat1 (0.5 μM) was incubated with SUMO-1 (2 μM), E1 assays 20 μg of a GAS oligonucleotide (see Table 1S ) coupled to 75 μl biotinylated agarose beads (Sigma, St Louis, MO) was incubated with 400 μl whole cell extracts (WCEs) for 2 h at 4 o C, after blocking the beads with 1% BSA for 1 h at 4 o C, as previously reported 43 . For immunoprecipitation, 400 μl of WCEs was incubated with primary antibody for 2-16 h followed by protein A agarose (Sigma, St. Louis, MO), and then collected, as previously reported 9, 34 .
WCE or precipitates were fractionated by SDS-PAGE and then evaluated by immunoblotting with the appropriate antibody 9 . For Nickel pulldown, 800 μl of WCEs was incubated with 100
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From μl of ProBond nickel beads, washed and eluted as per manufacturer (In vitrogen, Carlsbad, CA).
For electrophoretic mobility shift assay (EMSA) extracts were incubated with a GAS probe and fractionated by native PAGE as previously described 9, 34 . Antibodies were directed against Plasmid Constructs: pClEco and pMIG were provided by J. Luban (Columbia University) 41 .
Murine Stat1, Stat1 K703R and Stat1 E705A were cloned into the Xho I site in pMIG. Stat1 K703R and Stat1 E705A were prepared by site directed mutagenesis (Quickchange kit, Stratagene, La Jolla, CA) and confirmed by sequencing (see Table 1S for primer sequences).
Immunofluorescence: Cells were cultured on sterile cover slips till 20-25% confluent, fixed in formaldehyde, and stained as previously reported 9 , with Stat1 specific antibodies (1:250 fold dilution) and a Cy3-conjugated secondary antibody (1:500; Jackson ImmunoResearch Laboratories Inc., West Grove, PA). Slides were examined under a Nikon Eclipse TE300
microscope after excitation at 550 nm (Cy3) and excitation at 495 nm (GFP). and then reverse transcribed with SuperScript™ II (Invitrogen, Carlsbad, CA). The cDNA was quantitatively amplified in an ABI Prism 7700 PCR system, with a SYBR green master mix (Applied Biosystems, Foster City, CA), as previously described 32 . Gene expression was normalized to a β-actin control.
RNA expression analysis:
Luciferase reporter assay: MEFs were seeded in 24 well plates (7.5 x 10 5 /well) and transfected with 400 ng of an IRF driven luciferase reporter (i.e., B2WT3 44 ) and 40 ng of pRL-tk Renilla in LipofectAmine plus (Invitrogen, Carlsbad, CA). 24 hrs later transfectants were stimulated with IFN-γ (5 U/ml, 6 hrs), resuspended in a passive lysis buffer, and evaluated in a luminometer (TD 20/20 Turner Systems, Sunnyvale, CA), as previously reported 44 . Experiments were done in triplicate and luciferase activity was normalized to renilla activity.
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